Insilico Medicine vs XtalPi (2026)
Two listed Asian platform companies that both got a molecule into humans, which puts them ahead of most of this category regardless of methodology. Insilico has the cleanest narrative: its target engine picked the target, its generative chemistry engine designed the molecule, the discovery was published in peer reviewed literature and the lead asset carries orphan drug designation. XtalPi closes the loop physically, pairing quantum calculations and generative design with large scale robotic synthesis, so molecules are made and tested rather than proposed. If you want designs turned into physical compounds without building the laboratory, XtalPi sells that loop. If you want a platform with a documented path from target to clinic, Insilico has published it. Both select the target, design the molecule and report the result, which is worth remembering when reading either.
- It has the cleanest end to end case in the category, with one engine prioritising the target, another generating the molecule and the resulting drug reaching the clinic, published in peer reviewed literature.
- Orphan drug designation on a lead asset is a real external checkpoint rather than a platform description.
- The platform is sold as software as well as run internally, with named engines and disclosed methods, so a customer can license the tools rather than only partner.
- It closes the loop physically, combining quantum calculations and generative models with large scale robotic synthesis so designs are made and tested rather than only proposed.
- A stock exchange listing forces the most granular commercial disclosure here, so the split between software and services revenue is visible.
- A platform derived molecule is in humans, which is the evidence class that separates a platform from a story.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Insilico Medicine and XtalPi are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Insilico Medicine | XtalPi |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2014 | 2015 |
| Headquarters | Cambridge, Massachusetts | Shenzhen, China and Boston, MA |
| Website | insilico.com | en.xtalpi.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Insilico Medicine its top capability grade on AI Centrality, Clinical and Operational Evidence and FDA and Regulatory Status. Set against XtalPi, Insilico Medicine grades higher on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards XtalPi its top capability grade on Commercial Transparency and Setting and Specialty Coverage. Set against Insilico Medicine, XtalPi grades higher on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and AI Governance and Bias Disclosure. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Insilico Medicine or XtalPi?
On the axes where the AI Health Index separates them, Insilico Medicine grades higher on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence, and XtalPi grades higher on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and AI Governance and Bias Disclosure. Insilico Medicine leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Insilico Medicine and XtalPi differ most?
The widest separation the AI Health Index records between Insilico Medicine and XtalPi is on Commercial Transparency, where Insilico Medicine grades C and XtalPi grades A. That axis sits in the Commercial group, so it should carry the most weight for a buyer whose binding constraint is contracting, scope and what the price actually covers.
Where do Insilico Medicine and XtalPi grade the same?
The AI Health Index grades Insilico Medicine and XtalPi the same on several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and Security Certifications and Trust Center. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Insilico Medicine and XtalPi not disclosed?
At the last review, at least one of Insilico Medicine and XtalPi published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both companies are simultaneously platform vendors and drug developers, which is the structural conflict to hold while reading their evidence: the same organisation selects the target, designs the molecule, runs the analysis and reports the result. Read the revenue mix on both, since a large services component means part of what feels like platform capability is people doing work. XtalPi names its components freely and never quantifies their performance publicly. Neither holds a located security attestation, and neither publishes cohort or data provenance detail for the models behind the designs.